FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, specifically phthisiology, and can be used to treat active tuberculosis infection. Methods of the invention comprise administering to a mammal an immunologically effective amount of a therapeutic vaccine comprising an isolated fusion polypeptide comprising a combination of antigens Rv1813, Rv3620, Rv3619 and Rv2608 in combination with chemotherapeutic agents.
EFFECT: use of the inventions prolongs survival when treating an active tuberculosis infection and shortens the duration of chemotherapy.
41 cl, 4 tbl, 32 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HYBRIDISATION OF HETEROOLIGOMER MYCOBACTERIAL ANTIGENS | 2015 |
|
RU2695462C2 |
| MULTI-EPITOPE POLYPEPTIDE FOR IMMUNIZATION AGAINST MYCOBACTERIUM TUBERCULOSIS | 2023 |
|
RU2824195C1 |
| INTRANASAL VACCINE INDUCING CELL-MEDIATED IMMUNITY | 2019 |
|
RU2796973C2 |
| POLYANTIGENIC VACCINE FOR PREVENTING AND ADJUNCTIVE TREATMENT OF TUBERCULOSIS | 2019 |
|
RU2724896C1 |
| LIPOSOME FORMULATION SUITABLE FOR TREATING OR PREVENTING TUBERCULOSIS | 2012 |
|
RU2648842C2 |
| SYNTHETIC GLUCOPYRANOSYLLIPID ADJUVANTS | 2010 |
|
RU2560182C2 |
| SYNTHETIC GLUCOPYRANOSYL LIPOID ADJUVANTS | 2010 |
|
RU2732574C2 |
| COMPOSITION CONTAINING TLR AGONIST AND METHODS FOR ITS APPLICATION | 2017 |
|
RU2761870C2 |
| COMBINATION OF RECOMBINANT MICROBACTERIUM AND BIOLOGICALLY ACTIVE AGENT AS VACCINE | 2005 |
|
RU2495677C2 |
| NANO-ALUMINUM-PARTICLES CONTAINING SIZE-REGULATING AGENT | 2017 |
|
RU2753874C2 |
